# Jazz Pharmaceuticals

> Jazz Pharmaceuticals is a VC fund backing Medical Device and Wearables. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Palo Alto, United States
- Total investments: 4
- Last investment: Jul 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/jazz-pharmaceuticals
- Website: https://www.jazzpharma.com/
- Facebook: http://www.facebook.com/pages/Jazz-Pharmaceuticals/160408433982020

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its productsinclude Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended-release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive-compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome.

## Contacts

5 contacts available for Jazz Pharmaceuticals. Shizune tracks 12 team members at Jazz Pharmaceuticals. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/jazz-pharmaceuticals?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 3 | 75% |
| Wearables | 2 | 50% |
| Health Care | 2 | 50% |
| Nanotechnology | 2 | 50% |
| Medical | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 2 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bruce Cozadd | Chief Executive Officer | 0 | — |
| Chris Tovey | Chief Operating Officer | 0 | — |
| Dennis Engelke | Executive Director, Country Manager Switzerland & Austria | 0 | — |
| Fintan Keegan | Executive Vice President, Technical Operations | 0 | — |
| Iain McGill | Head of EUSA International and SVP, Jazz Pharmaceuticals | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Onera Health | Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life ofpatients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. | $12.5M | Series B | Jul 29, 2021 | http://www.onerahealth.com |
| Onera Health | Onera is a spin-off of imec, the world-leading research center for nanoelectronics and digital technology. Onera’s mission is to advance sleep medicine by creating breakthrough diagnostic solutions and services, helping millions of people who struggle with sleep-related ailments, and ultimately improving the health and quality of life for patientsaround the world. Onera is headquartered in California’s Silicon Valley and has R&D offices in the Netherlands. For more information, please visit www.onerahealth.com | $11.5M | Series B | Jul 29, 2021 | https://www.onerahealth.com/ |
| Onera Health | Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life ofpatients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. | $9.1M | Series A | Apr 24, 2019 | http://www.onerahealth.com |
| Arrivo BioVentures LLC | Our expertise is drug development. Whether we are developing a reformulated product, a new chemical entity, or a biologic, the team at Arrivo BioVentures has expertise in identifying regulatory strategies to expedite the path to approval and the efficient implementation of the clinical programs themselves. We coordinate with the FDA (and otherregulatory bodies) early and often to gain agreement on the development programs for our products, minimizing surprises and speeding implementation. | $49M | Series A | May 25, 2016 | http://arrivobio.com/ |

4 of 4 investments shown.

## Co-investors
- [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom) — VC Fund, 3 deals together
- [imec.xpand](https://shizune.co/investors/profile/imec-xpand) — VC Fund, 3 deals together
- [15th Rock](https://shizune.co/investors/profile/15th-rock) — VC Fund, 2 deals together
- [Innovation Industries](https://shizune.co/investors/profile/innovation-industries) — VC Fund, 2 deals together
- [Invest-NL](https://shizune.co/investors/profile/invest-nl) — VC Fund, 2 deals together
- [imec](https://shizune.co/investors/profile/imec) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jazz Pharmaceuticals invest in?

Jazz Pharmaceuticals invests primarily in Medical Device, Wearables and Health Care startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Jazz Pharmaceuticals?

Public channels for Jazz Pharmaceuticals include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Jazz Pharmaceuticals?

The team at Jazz Pharmaceuticals includes Bruce Cozadd (Chief Executive Officer), Chris Tovey (Chief Operating Officer) and Dennis Engelke (Executive Director, Country Manager Switzerland & Austria), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co